Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.

Experts Highlight Noteworthy Research From the 2024 ESMO Congress

MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.

MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma

Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.

PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma 

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Biomarker Consortium

Subscribe

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Xiaojia Wang, MD, discusses findings for ivonescimab plus chemotherapy in metastatic triple-negative breast cancer.

First-Line Ivonescimab Plus Chemotherapy Demonstrates Efficacy in Advanced TNBC

Sung Gwe Ahn, MD, PhD, discusses survival outcomes with ovarian function suppression-based endocrine therapy based on the HERA trial in HR-positive, HER2-positive breast cancer. 

Addition of OFS to Endocrine Therapy Improves Survival in HR+, HER2+ Early Breast Cancer

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.

2024 Regulatory Approvals Across NSCLC Propel the Therapeutic Landscape Forward 

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Jairam Krishnamurthy, MD, FACP, discusses factors that influence his choice between ribociclib and abemaciclib in the adjuvant breast cancer setting.

Adjuvant Ribociclib Revamps HR+/HER2– Breast Cancer Management

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

ESMO 2024: Treatment of uHCC

Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

Video content above is prompted by the following:

Briefly explore the current landscape of first-line treatment for unresectable hepatocellular carcinoma

Videos

Panelists discuss how recent advancements in frontline and second-line therapies for unrespectable hepatocellular carcinoma (uHCC) are reshaping treatment strategies and improving patient outcomes.

Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Treatment Decisions Based on BLCL Stage

Panelists discuss  current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Current Treatment in First Line –  IO + TKI or IO + IO

Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.

Use of monotherapy (IO or TKI) or localized treatment in First Line

Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP: 1.Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP: 2.Treatment Decisions Based on BLCL Stage

EP: 3.Current Treatment in First Line – IO + TKI or IO + IO

EP: 4.Use of monotherapy (IO or TKI) or localized treatment in First Line

Latest Conference Coverage